Medexus Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Medexus Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
32.1%
Buyback Yield
| Total Shareholder Yield | 32.1% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Feb 19 Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity.Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Jan 19
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Dec 05Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Nov 05There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 10Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 31The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if MDP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDP's dividend payments have been increasing.
Dividend Yield vs Market
| Medexus Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (MDP) | n/a |
| Market Bottom 25% (CA) | 2.0% |
| Market Top 25% (CA) | 6.6% |
| Industry Average (Pharmaceuticals) | 2.7% |
| Analyst forecast (MDP) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate MDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate MDP's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDP has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 09:55 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medexus Pharmaceuticals Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |